ヒトにおける猫アレルギーの世界市場-2024～2032年

世界のヒトにおける猫アレルギー市場は、2023年に7億3,000万米ドルに達し、2032年には11億9,000万米ドルに達すると予測され、予測期間2024～2032年のCAGRは5.6%で成長する見込みです。

猫アレルギーは、くしゃみ、鼻水、咳、じんましん、目の充血やかゆみ、皮膚の発疹など、人間にさまざまな症状を引き起こします。喘息に非常に敏感な一部の集団では、猫アレルゲンに暴露されることで喘息が悪化することがあります。これらの猫アレルゲンには、唾液、尿、ふけなどに含まれるタンパク質が含まれます。ヒトのアレルギーを引き起こすタンパク質／アレルゲンは8種類知られており、（Fel d 1からFel d 8まで）分類されています。

ヒトの猫アレルギーに対する最も一般的な治療法には、抗ヒスタミン薬、ステロイド点鼻薬、鼻づまり除去スプレー、ロイコトリエン拮抗薬などがあります。猫アレルギーに特化した免疫療法薬は今のところ承認されていないため、治療アルゴリズムには症状の管理が含まれます。

ヒトにおける猫アレルギー市場は、ペットの飼育率の上昇、研究開発の活発化、新薬開発活動によって牽引されると予測されます。

市場力学：

促進要因と阻害要因

猫の飼育率の上昇がヒトにおける猫アレルギー市場を牽引

世界的にペットの飼育率は上昇しており、中でも犬や猫が人気です。このようなペットの飼育率の上昇は、ペットとのふれあいによる精神的なメリットに対する意識の高まり、動物福祉に対する意識の高まり、都市化の進展、ペットのニーズに応えるための可処分所得の増加などによって促進されています。ペット飼育率の上昇と同様に、ペットアレルギーの人口も世界的に増加しています。例えば、Asthma and Allergy Foundation of Americaによると、世界人口の10～20％近くがペット、特に犬猫にアレルギーがあり、このアレルギー人口は世界的に増加しています。

さらに、喘息患者は猫アレルギーのリスクが高く、アナフィラキシー（生命を脅かす重篤なアレルギー反応）の発生率も高いです。喘息の世界の有病率の上昇に伴い、これらの人口は猫アレルギーのリスクが高くなっています。例えば、2024年9月にChinese Medical Journal Pulmonary and Critical Care Medicineに掲載された研究によると、2030年の新規喘息患者発生率は、2020年の644万人から1,190万人に達すると予想されています。同様の動向は、世界中のすべての国で観察されています。米国では、2020年の537万症例から、2030年には694万症例近くの新規喘息症例が報告されると予想されています。

ペットの飼育率に関しては、米国獣医師会の発表によれば、米国の猫人口は2020年の6,500万匹から2030年には8,200万匹以上に激増すると予想されています。

この増加傾向は、猫アレルギーを持つ人口の増加と相まって、高度な治療に対する需要を大幅に増加させ、予測期間における市場全体の成長を促進する可能性があります。

猫アレルギーの過少報告は市場の成長を大きく阻害する可能性があります。

猫のアレルゲンに長期間さらされた後に猫アレルギーを発症する人の多くは、ほとんどの場合、その症状はアレルギー性鼻炎と誤診されます。多くの人は医師に相談したり症状を報告したりしないため、症例の過少報告につながり、連続して治療率の低下につながる可能性があります。これは発展途上国では大きな障壁となり、治療率の低下につながります。このような過少報告は、免疫療法などの新薬開発の妨げにもなります。これらすべての要因が、予測期間における市場成長の妨げとなる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 猫の飼育増加
    • 研究開発と新薬開発活動の増加
  • 抑制要因
    • 猫アレルギーの報告不足
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• パイプライン分析
• 疫学
• 特許分析
• 規制分析

第6章 治療薬の種類別

• 抗ヒスタミン薬
  • ジフェンヒドラミン
  • アゼラスチン
  • ロラタジン
  • セチリジン
  • その他
• コルチコステロイド
  • プロピオン酸フルチカゾン
  • モメタゾンフロエート
  • トリアムシノロン
  • その他
• 鼻づまり除去薬
• ロイコトリエン拮抗薬
• その他

第7章 投与経路別

• 経口
• 経鼻
• 非経口

第8章 処方方法別

• OTC (Over-the-Counter)
• 処方箋

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Kenvue Brands LLC.
  • 会社概要
  • 治療タイプのポートフォリオと説明
  • 財務概要
  • 主な発展
• Bayer AG
• Sanofi
• Haleon Group of Companies.
• GSK Plc.
• Johnson & Johnson Services, Inc.
• Teva Pharmaceuticals USA, Inc.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Perrigo Company.

第13章 付録

The global cat allergy in human market reached US$ 0.73 billion in 2023 and is expected to reach US$ 1.19 billion by 2032, growing at a CAGR of 5.6% during the forecast period 2024-2032.

Cat allergy can cause various symptoms in humans such as sneezing, runny nose, cough, hives, red and itchy eyes, rashes on skin, etc. In some very sensitive populations with asthma, exposure to cat allergens may cause severe asthma flare-ups. These cat allergens include proteins in saliva, urine, dander, etc. There are eight known proteins/allergens that cause allergies in human, classified from (Fel d 1 to Fel d 8), and the most common culprit is Fel d 1- causing the majority of cases.

The most common treatment options for cat allergy in humans include antihistamines, steroidal nasal sprays, decongestant nasal sprays, leukotriene antagonists, etc. No immunotherapy drugs have been approved till now specifically for cat allergy, hence the treatment algorithm includes managing the symptoms.

The market for cat allergy in human is aniticipated to be driven by the rising pet adoption rates, rising R&D, and novel drug development activities.

Market Dynamics: Drivers & Restraints

The rising adoption of cats is driving cat allergy in human market

Globally, the ownership of pets is rising, among them, dogs and cats are the popular ones. This rising adoption is fostered by increasing awareness of mental benefits caused by pet companionship, increasing awareness of animal welfare, rising urbanization, and increasing disposable income to cater to the needs of pets, etc. Similar to the rising pet adoption rate, the number of population who are allergic to pets is also rising globally. For instance, according to the Asthma and Allergy Foundation of America, nearly 10 to 20% of the global population is allergic to pets, especially cats and dogs, and this allergic population is rising globally.

Moreover, asthmatic patients are at a higher risk of cat allergies and related incidence of anaphylaxis (a serious life-threatening allergic reaction). As the global prevalence of asthma is rising, these populations are at a higher risk of cat allergy. For instance, a study published in the Chinese Medical Journal Pulmonary and Critical Care Medicine in September 2024, stated that the incidence of new asthma cases in 2030 is expected to reach 11.90 million from 6.44 million in 2020. A similar trend is observed in all the countries across the world. In the U.S. nearly 6.94 million new asthma cases are expected to be reported in 2030, from 5.37 million cases in 2020.

Concerning the pet adoption rate, as per the American Veterinary Medical Association, the cat population in the U.S. is expected to drastically rise from 65 million in 2020 to more than 82 million in 2030.

This increasing trend coupled with a rising population who are allergic to cats can significantly increase the demand for advanced therapies and propel the overall market growth in the forecast period.

Underreporting of cat allergy can significantly hinder cat allergy in human market growth.

Many individuals develop cat allergy after prolonged exposure to cat allergens, and most of the time, the symptoms are misdiagnosed as allergic rhinitis. Many individuals may not consult or report their symptoms to the doctor, which may lead to underreporting of cases and consecutively lead to lower treatment rates. This can be a significant barrier in underdeveloped countries, leading to a lower treatment rate. This underreporting can also hinder the development of novel drugs such as immunotherapies because the manufacturers may not see the area to be potential for exploration. All of these factors can hinder the market growth in the forecasted period.

Segment Analysis

The global cat allergy in human market is segmented based on treatment type, route of administration, mode of prescription, distribution channel, and region.

Antihistamines in the treatment type segment have the highest market share.

Antihistamines are the drugs designated for the treatment of allergy symptoms and are prescribed for the treatment of various allergic conditions including pet allergy. Antihistamines work by inhibiting the histaminic receptors that are involved in the allergy-induced inflammatory response pathway. Antihistamines that are aimed at treating allergies act specifically on H-1 receptors, and nearly 45 H1 receptor antagonists have been discovered till now. The research efforts to discover novel next-generation antihistamines are still ongoing and manufacturers are investing heavily to bring them into the market and tackle the growing need of the allergic population.

For cat allergy, the commonly used antihistamines are fexofenadine, loratadine, desloratadine, cetirizine, levocetirizine, etc. All these drugs antagonize the H1 receptors and prevent the binding of histamine, a major transmitter released in response to cat allergen. Drugs acting through this mechanism act quickly and address the bothering symptoms of cat allergy. Moreover, these drugs are available over the counter and have minimal side effects, making them the preferred choice of drugs by both physicians and patients.

Geographical Analysis

North America is expected to hold a significant share of the cat allergy in human market.

North America is estimated to hold the highest market share throughout the forecast period, owing to factors like increasing pet ownership, rising population who are allergic to cats, heightened awareness of cat allergies, and strong presence of market players who are offering advanced therapies.

Moreover, the population in the region is highly aware of their allergic symptoms and consults physicians regularly. This results in a higher treatment rate for cat allergy in the region. Moreover, the drugs that are commonly prescribed for cat allergy are widely available in the U.S. both in branded and generic versions. For instance, popular brands such as "Zyrtec" by Kenvue Brands LLC., "Allegra" by Sanofi, and "Benadryl" by Johnson & Johnson Services, Inc. are the most popular drugs for cat allergy in the region. These drugs are available in the U.S. through various distribution channels providing easy access to patients.

Hence all these factors including the revenue generated by the market players contribute to the region's dominance in the global cat allergy in human market.

Competitive Landscape

The major global players in the cat allergy in human market are Kenvue Brands LLC., Bayer AG, Sanofi, Haleon Group of Companies., GSK Plc., Johnson & Johnson Services, Inc., Teva Pharmaceuticals USA, Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., and Perrigo Company. among others.

Emerging Players

The emerging players in the cat allergy in human market include ANGANY Inc. among others.

Key Developments

• In January 2024, ANGANY Inc., announced the positive results of phase 1 clinical trials for its novel biological drug ANG-101. Angany is the first company to initiate clinical trials for cat allergy in humans. The investigational candidate which is an immunotherapy drug showed a significant safety profile, with mild and reversible side effects among the subject population.
• In August 2024, the U.S. Food and Drug Administration (FDA) approved neffy (epinephrine nasal spray) for the treatment of type 1 allergic reactions including life-threatening anaphylaxis. Neffy demonstrated a significant improvement in blood pressure, and heart rate, similar to epinephrine injection. Although anaphylaxis is rare in cat allergy patients, this can be a life-saving treatment in the particular population group who experience it.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and Treatment Type pipelines, and forecasts upcoming pharmaceutical advancements.
• Treatment Type Performance & Market Positioning: Analyzes Treatment Type performance, market positioning, and growth potential to optimize strategies.
• Real-world Evidence: Integrates patient feedback and data into drug-enzyme-type development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Treatment Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Cat allergy in human market report would provide approximately 70 tables, 64 figures, and 170 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Mode of Prescription
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising adoption of cats
    • 4.1.1.2. Rising R&D and novel drug development activities
  • 4.1.2. Restraints
    • 4.1.2.1. Underreporting of cat allergy
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Epidemiology
• 5.6. Patent Analysis
• 5.7. Regulatory Analysis

6. By Treatment Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 6.1.2. Market Attractiveness Index, By Treatment Type
• 6.2. Antihistamines*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Diphenhydramine
  • 6.2.4. Azelastine
  • 6.2.5. Loratadine
  • 6.2.6. Cetirizine
  • 6.2.7. Others
• 6.3. Corticosteroids
  • 6.3.1. Fluticasone Propionate
  • 6.3.2. Mometasone Furoate
  • 6.3.3. Triamcinolone
  • 6.3.4. Others
• 6.4. Nasal Decongestants
• 6.5. Leukotriene Antagonists
• 6.6. Others

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Oral*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Nasal
• 7.4. Parenteral

8. By Mode of Prescription

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
• 8.2. Market Attractiveness Index, By Mode of Prescription
• 8.3. Over-the-Counter*
  • 8.3.1. Introduction
  • 8.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.4. Prescription Based

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. The U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Kenvue Brands LLC.*
  • 12.1.1. Company Overview
  • 12.1.2. Treatment Type Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Bayer AG
• 12.3. Sanofi
• 12.4. Haleon Group of Companies.
• 12.5. GSK Plc.
• 12.6. Johnson & Johnson Services, Inc.
• 12.7. Teva Pharmaceuticals USA, Inc.
• 12.8. Sun Pharmaceutical Industries Ltd.
• 12.9. Viatris Inc.
• 12.10. Perrigo Company.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us